DRAK2 siRNA (m): sc-38982



The Power to Question

BACKGROUND

DAP (death associated protein) kinase and ZIP kinase are members of a novel protein kinase family, the members of which have the capacity to mediate apoptosis through their catalytic activities. DAP kinase contains a "death domain" and has been shown to mediate γ interferon-induced apoptosis. The introduction of DAP kinase into highly metastatic carcinoma clones lacking DAP kinase expression was shown to result in the suppression of metastasis, thus linking suppression of apoptosis to metastasis. ZIP kinase contains a leucine zipper domain, which is necessary for homodimerization and for interaction with other leucine zipper proteins. ZIP kinase dimerizes with ATF-4, an ATF/CREB transcription factor family member that contains a leucine zipper. DRAK1 (DAP kinase-related apoptosis-inducing protein kinase 1) and DRAK2 are DAP kinase related proteins. DRAK1 and DRAK2 are localized to the nucleus, and overexpression of both DRAK proteins in NIH/3T3 cells induces morphological changes associated with apoptosis.

REFERENCES

- Hai, T.W., et al. 1989. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev. 3: 2083-2090.
- Deiss, L.P., et al. 1995. Identification of a novel serine/threonine kinase and a novel 15 kDa protein as potential mediators of the γ interferon-induced cell death. Genes Dev. 9: 15-30.
- 3. Sakagami, H., et al. 1997. Molecular cloning and developmental expression of a rat homologue of death-associated protein kinase in the nervous system. Brain Res. Mol. Brain Res. 52: 249-256.
- Inbal, B., et al. 1997. DAP kinase links the control of apoptosis to metastasis. Nature 390: 180-184.
- Sanjo, H., et al. 1998. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J. Biol. Chem. 273: 29066-29071.
- Kawai, T., et al. 1998. ZIP kinase, a novel serine/threonine kinase which mediates apoptosis. Mol. Cell Biol. 18: 1642-1651.

CHROMOSOMAL LOCATION

Genetic locus: Stk17b (mouse) mapping to 1 C1.1.

PRODUCT

DRAK2 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see DRAK2 shRNA Plasmid (m): sc-38982-SH and DRAK2 shRNA (m) Lentiviral Particles: sc-38982-V as alternate gene silencing products.

For independent verification of DRAK2 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-38982A, sc-38982B and sc-38982C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

DRAK2 siRNA (m) is recommended for the inhibition of DRAK2 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

DRAK2 (C-2): sc-398324 is recommended as a control antibody for monitoring of DRAK2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor DRAK2 gene expression knockdown using RT-PCR Primer: DRAK2 (m)-PR: sc-38982-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.